JP2011525531A5 - - Google Patents

Download PDF

Info

Publication number
JP2011525531A5
JP2011525531A5 JP2011516297A JP2011516297A JP2011525531A5 JP 2011525531 A5 JP2011525531 A5 JP 2011525531A5 JP 2011516297 A JP2011516297 A JP 2011516297A JP 2011516297 A JP2011516297 A JP 2011516297A JP 2011525531 A5 JP2011525531 A5 JP 2011525531A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
brain lesions
human subject
once
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011516297A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011525531A (ja
JP5988581B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/003760 external-priority patent/WO2010008474A2/en
Publication of JP2011525531A publication Critical patent/JP2011525531A/ja
Publication of JP2011525531A5 publication Critical patent/JP2011525531A5/ja
Application granted granted Critical
Publication of JP5988581B2 publication Critical patent/JP5988581B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011516297A 2008-06-23 2009-06-23 アンチセンスオリゴヌクレオチドを用いる多発性硬化症の治療方法 Expired - Fee Related JP5988581B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13297308P 2008-06-23 2008-06-23
US61/132,973 2008-06-23
PCT/US2009/003760 WO2010008474A2 (en) 2008-06-23 2009-06-23 Methods for treating multiple sclerosis using antisense oligonucleotides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014208153A Division JP6131230B2 (ja) 2008-06-23 2014-10-09 アンチセンスオリゴヌクレオチドを用いる多発性硬化症の治療方法

Publications (3)

Publication Number Publication Date
JP2011525531A JP2011525531A (ja) 2011-09-22
JP2011525531A5 true JP2011525531A5 (enExample) 2012-08-09
JP5988581B2 JP5988581B2 (ja) 2016-09-07

Family

ID=41550900

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011516297A Expired - Fee Related JP5988581B2 (ja) 2008-06-23 2009-06-23 アンチセンスオリゴヌクレオチドを用いる多発性硬化症の治療方法
JP2014208153A Expired - Fee Related JP6131230B2 (ja) 2008-06-23 2014-10-09 アンチセンスオリゴヌクレオチドを用いる多発性硬化症の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014208153A Expired - Fee Related JP6131230B2 (ja) 2008-06-23 2014-10-09 アンチセンスオリゴヌクレオチドを用いる多発性硬化症の治療方法

Country Status (8)

Country Link
US (2) US8415314B2 (enExample)
EP (2) EP2937358B1 (enExample)
JP (2) JP5988581B2 (enExample)
AU (1) AU2009271678B2 (enExample)
CA (1) CA2728562C (enExample)
DK (2) DK2937358T3 (enExample)
ES (2) ES2532404T3 (enExample)
WO (1) WO2010008474A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010008474A2 (en) 2008-06-23 2010-01-21 Teva Pharmaceutical Industries, Ltd. Methods for treating multiple sclerosis using antisense oligonucleotides
US20130323196A1 (en) 2010-09-17 2013-12-05 Antisense Thereapeutics Ltd Method for mobilizing stem and/or progenitor cells
AU2016259971B2 (en) 2015-05-11 2021-12-09 ProGenis Pty Ltd Multiple sclerosis treatment
CA3067193A1 (en) * 2017-06-16 2018-12-20 Antisense Therapeutics Ltd Methods for treating multiple sclerosis using antisense oligonucleotides
EP3787639A4 (en) 2018-05-04 2022-02-23 Antisense Therapeutics Ltd THERAPEUTIC USES AND PROCESSES
BR112021022208A2 (pt) * 2019-05-06 2022-01-11 Antisense Therapeutics Ltd Métodos para tratamento de distrofia muscular usando oligonucleotídeos inibidores para cd49d

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242591B1 (en) * 1997-10-15 2001-06-05 Isis Pharmaceuticals, Inc. Synthesis of sulfurized 2'-substituted oligonucleotides
US5968826A (en) * 1998-10-05 1999-10-19 Isis Pharmaceuticals Inc. Antisense inhibition of integrin α4 expression
WO2005108610A2 (en) * 2004-04-05 2005-11-17 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for the selection of subjects for multiple sclerosis therapy
AU2005327506B2 (en) * 2004-10-20 2010-07-08 Antisense Therapeutics Ltd Antisense modulation of integrin alpha4 expression
WO2010008474A2 (en) 2008-06-23 2010-01-21 Teva Pharmaceutical Industries, Ltd. Methods for treating multiple sclerosis using antisense oligonucleotides

Similar Documents

Publication Publication Date Title
WO2009154777A4 (en) Process for preparing and drying solid rasagiline base
JP6752151B2 (ja) 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー
JP2012530715A5 (enExample)
CA2856646C (en) Combination treatment of cancer
EP2978845B1 (en) Modified tgf-beta oligonucleotides
JP2011525531A5 (enExample)
JP2013535437A5 (enExample)
RU2015139553A (ru) Композиции и способы модуляции smn2 сплайсинга у субъекта
JP2018520685A (ja) Ｂ型肝炎ウイルスに対する組成物および薬剤ならびにその使用
JP2018082703A5 (enExample)
JP2018512127A5 (enExample)
JP2012144512A (ja) 脳腫瘍を治療するための医薬組成物又は脳腫瘍細胞のテモゾロミド耐性を低減させるための医薬組成物、及びその使用
JP2016513110A5 (enExample)
JPWO2020061177A5 (enExample)
JP2024037841A5 (enExample)
JP5674923B2 (ja) アンチセンスオリゴヌクレオチドを含む医薬組成物およびそれを使用する方法
KR20140025461A (ko) 진행성 고형 종양의 치료 방법
WO2023004049A1 (en) Unc13a antisense oligonucleotides
US20240229028A1 (en) Splice-switching oligonucleotides and methods of use
AU2016287580A2 (en) Compositions and methods for the treatment of viral infection
JP2014513144A (ja) 進行性又は転移性固形悪性腫瘍を含む固形悪性腫瘍の治療方法
WO2010008474A4 (en) Methods for treating multiple sclerosis using antisense oligonucleotides
AU2005327506B2 (en) Antisense modulation of integrin alpha4 expression
US9688988B2 (en) Modified TGF-beta oligonucleotide for use in a method of preventing and/or treating an ophthalmic disease
US20230113556A1 (en) Antisense nucleic acid targeting apoc3